The strong Cohort C data de-risks TSC-101's manufacturing and efficacy profile ahead of the Phase 3 ALLOHA-2 trial initiation. Monitor for enrollment updates and subsequent Cohort C data readouts over the next 12-18 months, which will provide further validation of the commercial-ready process and support the pivotal trial.
Drug in focus
TCRX drug pipeline →TSC-101
▼ Bearish Named in this 8-K- Impact
- Phase
- Phase 3 (paused)
- Time to market
- Uncertain. The Phase 3 trial is paused due to insufficient capital, and the company is seeking a partner to continue development. Even if partnered, a pivotal trial would need to complete before any regulatory filing, putting potential approval years away.
- Next catalyst
- None dated
What to watchTSC-101's development is paused, and the stock's fate hinges entirely on whether TScan can secure a partnership for the heme program. Without a partner, the Phase 3 trial will not resume and the program may be abandoned. The company's focus has shifted to preclinical solid tumor candidates, which are years from clinical data. Monitor for partnership announcements or a potential sale of the heme assets.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 22 $0.8651entry
- T+1 · 5mo ago +6.46%α +7.91% · $0.9210
- T+5 · 5mo ago +12.99%α +13.45% · $0.9775
- T+20 · 4mo ago +5.75%α +5.89% · $0.9148
- T+60 · 2mo ago −62.86%α −64.61% · $0.3213
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
TScan Therapeutics reported positive initial data from Cohort C of the ALLOHA Phase 1 study for TSC-101, showing 11 of 14 patients achieved complete donor chimerism within ~3 weeks of first infusion, with a 93% response rate and a ~90% manufacturing success rate using the commercial-ready process. The company remains on track to enroll the first patient in the pivotal Phase 3 ALLOHA-2 study this month, de-risking the program and supporting advancement toward a registrational trial.
Key Facts
- 11 of 14 patients achieved complete donor chimerism within ~3 weeks of first TSC-101 infusion
- 93% of patients (13/14) responded with decreasing recipient chimerism
- ~90% manufacturing success rate (17/19) with commercial-ready process
- Safety profile consistent with Cohort A; no new safety signals
- Company to enroll first patient in Phase 3 ALLOHA-2 study in June 2026
- $128.1M cash as of March 31, 2026, funding operations into H2 2027
Financial Impact
No financial data provided; clinical-stage biotech with $128.1M cash runway into H2 2027
Risk Factors
- Phase 3 trial may fail to replicate Phase 1 results
- Competition from other relapse-prevention therapies in post-transplant setting
- Need for additional financing beyond H2 2027 to complete Phase 3 and potential commercialization
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-276693 |
| Document: d103234d8k.htm | 0001193125-26-276693 |
| Document: d103234dex991.htm | 0001193125-26-276693 |
| Document: 0001193125-26-276693-index-headers.html | 0001193125-26-276693 |
| Document: 0001193125-26-276693-index.html | 0001193125-26-276693 |
| Document: 0001193125-26-276693.txt | 0001193125-26-276693 |
Track record
15 reports on TCRX
5 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +77.60% at T+60 after the Aug 18, 2026 report. 7 of 7 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Bearish 7/10 Entry $0.1680 Now $0.1450 +13.69% settles Nov 19
- Oct 26, 202621d ago DEF 14A Bearish 6/10 Entry $0.1897 to $0.1745 Now $0.1450 +23.56% ▲ +8.01% +6.75% vs SPY
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $0.2102 to $0.1897 Now $0.1450 −31.02% ▼ −9.75% −9.61% vs SPY
- Sep 30, 20266w ago 8-K Neutral 2/10 Entry $0.3175 to $0.2282 Now $0.1450 −54.33% ▼ −28.13% −29.43% vs SPY
- Sep 25, 20267w ago SC 13G Neutral 3/10 Entry $0.3400 to $0.2953 Now $0.1450 −57.35% ▼ −13.15% −14.35% vs SPY
- Sep 11, 20269w ago 8-K Neutral 5/10 Entry $0.3204 to $0.3119 Now $0.1450 −54.74% ▼ −2.65% −2.43% vs SPY
- Sep 2, 202610w ago 8-K Bearish 7/10 Entry $0.3810 to $0.3179 Now $0.1450 +61.94% ▲ +16.56% +15.60% vs SPY
- Aug 18, 202612w ago 8-K Bearish 7/10 Entry $0.7500 to $0.7774 Now $0.1450 +80.67% ▼ −3.65% −4.04% vs SPY
- Aug 12, 202613w ago 8-K Bearish 6/10 No price data
- Aug 12, 202613w ago Press Release Bearish 6/10 Entry $0.7730 to $0.7500 Now $0.1450 +81.24% ▲ +2.98% +2.53% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers